anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Two hundred and fifty stage II-IV gastric cancer patients who should receive neoadjuvant therapy, conversion therapy or palliative chemotherapy will be enrolled in this study. Baseline information of the enrolled patients including medical history, physical examination records and clinical examination records will be collected. Tumor material of those patients will be obtained from gastric endoscopic biopsies or surgical resection. Patient-derived organoids (PDOs) will be established and cultured from gastric cancer tumor specimens. PDOs will then be treated with drugs of the chemotherapeutic regimens for gastric cancer. Organoid size and growth will be monitored before and after the treatment, and dose-response curves will be generated. As for the assessment of clinical outcomes of patients, tumor regression grade (TRG) systems will be used to evaluate tumor histological responses, and treatment responses will also be assessed by biomedical imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1). Consistency between treatment responses in PDO models and clinical outcomes of patients will be assessed by correlation analysis.
IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
PURPOSE: To obtain a composition excellent in defoamability, preservability, dispersibility in water and antimicrobial effect, thus useful as a mouthwash, etc. CONSTITUTION: This composition for oral cavity comprises a defoaming agent composition prepared by emulsifying in water a composition comprising (a) 100 pts.wt. of a silicone oil compound composed of a liquid organopolysiloxane and fine silica powder, (b) 1-80 pts.wt. of an emulsifier composed of (1) 30-90wt.% of a sorbitan higher fatty acid ester with the 12-18C fatty acid constituent and (2) 10-70wt.% of a polyethylene glycol higher fatty acid monoester with the 12-18 fatty acid constituent, (c) 0.01-20 pts.wt. of a thickening agent, and (d) 0.01-20 pts.wt. of a antiseptic agent consisting of at least one kind selected from aromatic organic acids and unsaturated organic acids.
PURPOSE: An antibiotic peptide is provided to have excellent antibacterial activity against Escherichia coli or Staphylococcus aureus and to show thermal stability, thereby being used as an active ingredient of an antibacterial and antiseptic composition. CONSTITUTION: An antibiotic peptide has an amino acid sequence of sequence number 1 or 2. The antibiotic peptide is isolated from Nordotis discus discus and has thermal stability. An antibacterial or antiseptic composition contains the antibiotic peptide as an active ingredient. An antibacterial pharmaceutical composition contains the antibiotic peptide as an active ingredient. An antibacterial cosmetic composition contains the antibiotic peptide as an active ingredient.
An object of the present invention is to provide a patch-containing packaging pouch which enables stable storage of a patch containing bisoprolol in a pressure-sensitive adhesive layer. A packaged desiccant  1  of the present invention has a packaging pouch  8  composed of a pair of laminated package members  7   a  and  7   b  arranged in mutual opposition, and a patch  10  housed in the space within this packaging pouch  8 . Patch  10  is provided with a support  12  and a pressure-sensitive adhesive layer  14  laminated substantially over the entire surface of one side of this support  12 . In addition, the pressure-sensitive adhesive layer is composed of a pressure-sensitive adhesive composition containing a pressure-sensitive adhesive and bisoprolol or pharmaceutically acceptable salt thereof. Moreover, a packaged desiccant  20  is housed within packaging pouch  8 . The relative humidity within packaging pouch  8  is maintained at 25% or less in a patch-containing packaging pouch  1  having this constitution.
PROBLEM TO BE SOLVED: To obtain the subject material comprising a specific substance obtained from hop bracts generated as a byproduct on the brewing of beer and adsorbed to gel type synthetic resins, capable of being utilized for foods, drinks and oral cavity agents, exhibiting a strong deodorizing effect, and originated from the plant. SOLUTION: This deodorizing raw material comprises a polyphenol-like substance which is contained in the bracts of hop, is adsorbed on gel-like synthetic resins, and does not pass through an ultrafiltration membrane having a fractionation mol.wt. of >=1000, when treated with the ultrafiltration membrane. Namely, the deodorizing raw material comprises a fraction obtained by extracting the bracts of the hop with water or the aqueous solution of an organic solvent miscible with the water, treating the extract with a gel type synthetic adsorbent or an ultrafiltration membrane and further subjecting the filtrate to various processes. The gel type synthetic resin includes a hydrophilic vinylic polymer and a hydroxypropylated dextrin. The deodorizing material can be utilized for drinks and foods stayed for relatively long times, such as candies, chewing gums and chocolates.  The deodorizing material may be added to oral cavity agents such as gargles and dentifrices.
PCT No. PCT/SE86/00484 Sec. 371 Date May 22, 1987 Sec. 102(e) Date May 22, 1987 PCT Filed Oct. 17, 1986 PCT Pub. No. WO87/02382 PCT Pub. Date Apr. 23, 1987.The present invention relates to a process and means for separating motile sperm cells in vitro from an aqueous sperm-containing sample by means of contacting said sample with a layer of an aqueous artificial penetration medium for sperm cells, said medium having incorportated therein a water-soluble physiologically acceptable salf of hyaluronic acid, whereby motile sperm cells are caused to migrate into said layer from said sperm-containing sample. The invention also comprises fertilization with sperm cells separated in this manner.
Within the penile microbiome, bacteria associated with seroconversion, immunology, and cells (BASIC species) enhance HIV susceptibility in heterosexual uncircumcised men by inducing foreskin inflammation and HIV target cell recruitment. This phase 1/2 clinical trial randomizes HIV-uninfected Ugandan men (n = 125) to either oral tinidazole, topical metronidazole, topical clindamycin, or topical hydrogen peroxide to define impact on ex vivo foreskin HIV susceptibility, penile immunology, and BASIC species density. Antimicrobials are well tolerated, and 116 (93%) participants complete the protocol. Topical metronidazole and oral tinidazole reduce the inner foreskin tissue density of HIV-susceptible CD4+ T cells (predefined primary endpoint). Antimicrobials also have varying but substantial effects on reducing prepuce inflammation and BASIC species density, reducing density of foreskin T cell subsets, and increasing foreskin epithelial integrity. Immune alterations correlate strongly with changes in the abundance of BASIC species. Clinical interventions targeting the penile microbiota, particularly topical metronidazole, may reduce HIV susceptibility in uncircumcised men.
Research on socioeconomic position (SEP) and mild neurocognitive impairment, considered a transient state between normal cognitive function and dementia is limited. The purpose of this study was to determine the role of SEP in transitioning between different cognitive states and mortality risk. Using nationally representative English data and utilising a multistate model association between SEP and the risk of transitioning from no cognitive impairment (NOCI) to Cognitive impairment no dementia (CIND), dementia and death were investigated. The potential reverse transition from CIND to NOCI was also explored. The probabilities of transitioning between cognitive states and time spent in each state differed significantly between those with lower and higher levels of SEP. Higher wealth was associated with a reverse transition from CIND to NOCI [HR = 1.56, CI (1.42,1.72)]. Socioeconomic advantage might protect against the progression to the early stages of neurocognitive disorders (CIND) and facilitate the potential reversion from mild cognitive impairment to a healthy cognitive state in later life. Lower levels of education affect the risk of mortality after the onset of dementia.
1480510 Substituted 3,4-diphenylimidazolidines, their preparation and pharmaceutical compositions AKZO NV 11 Sept 1974 [20 Sept 1973] 39659/74 Heading C2C The invention comprises compounds of Formula I in which r and s are 0 or integers from 1-5; R 1  and R 2  are independently OH, halogen, C 1-6  alkoxy, C 1-8  acyloxy or CF 3  and R 3  is hydrogen, C 1-6  alkyl, aryl or C 7-9  aralkyl which may be prepared (a) by reacting a compound of Formula II in which Q represents two hydrogen atoms or an oxygen atom and r, s, R 1 , R 2  and R 3  are as defined above, with a reagent of general Formula III in which Y represents two hydrogen atoms, an oxygen atom or a sulphur atom and Z 1  and Z 2  independently represent a reactive or leaving group or together represent a trivalent reactive group, which groups can be eliminated together with the hydrogen atom of either nitrogen atom of the diamine II to form a compound of Formula IV in which r, s, R 1 , R 2 , R 3 , Y and Q are as defined above, followed by reduction, when Y and/or Q is oxygen or sulphur, to obtain the desired product, or (b) by N-alkylation of the imidazolidine compounds in which R 3  is hydrogen, in a known manner. 1 - Phenyl - 3 - m - tolyl - 3 - p - tolylamino - 2- methylaminoethane are obtained from their hydrochlorides by dissolving in aqueous ammonia and extracting into ether. 1 - Acetyl and 1 - benzoyl - 3,4 - diphenylimidazolidine are prepared by N - acylation of 3,4-diphenylimidazolidine with acetic anhydride or benzoyl chloride respectively. 1 - Methyl - 2 - oxo - 3 - m - tolyl - 4 - phenylimidazolidine and its thioketone analogue are prepared by reacting 1-phenyl-1-m-tolylamino- 2 - methylaminoethane with CS 2 , thiophosgene. phosgene, ethylchloroformate, dimethyl carbonate or N,N<SP>1</SP>-carbonyldiimidazol. Pharmaceutical compositions having anticholinergic and anticonvulsive activity for oral or parenteral administration comprise a compound of Formula I or an acid addition salt thereof together with suitable auxiliaries.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to immunology and biotechnology. Claimed are versions of antibodies or their functional fragments, which are bound with receptor of human insulin-like growth factor I IGF-IR, and/or natural binding of its ligands IGF1 and/or IGF2 and/or are capable of specific inhibition of tyrosine kinase activity of said IGF-IR. Antibodies contain respective CDR sections of light and heavy chains. Described is mouse hybridoma I-3193 for production of antibodies. Composition for prevention or treatment of cancer, based on antibody application. Described is application of antibodies and/or composition for obtaining respective medication. Claimed is method of diagnostics in vitro of diseases, caused by over-expression or insufficient expression of receptor IGF-I based on antibodies.. ^ EFFECT: invention application ensures antibodies able to bind with isophorms A and B insulin, insulin/ IGF-1 of hybrid receptors which can be applied in medicine for tumour treatment. ^ 15 cl, 8 dwg, 2 tbl, 4 ex
The pathological assessment of cystectomy specimens is important for accurate prognostic information and to inform adjuvant therapy decisions. However, there is limited evidence regarding the best approach to fixation, dissection, block selection and microscopic assessment of cystectomies. We report the results of an international survey of 212 pathologists and their approach to cystectomy pathology. There is variation at all stages of the specimen journey including in fixation and dissection techniques, and in the approach to evaluating residual tumour. This is particularly evident in the post-neoadjuvant chemotherapy setting where there is variable use of response scoring systems and differing approaches to sampling. We also find variation in the use of digital and molecular pathology in cystectomy specimens. Finally, we have suggested areas for future research in cystectomy pathological assessment.
BACKGROUND: Preeclampsia is still a disease whose cause and treatment have not been fully characterised. Early-onset preeclampsia occurs before the 34th week of pregnancy, and late-onset preeclampsia occurs at 34 weeks or older. In our study, we investigated whether the prognostic nutritional index (PNI) and pan immune inflammation value (PIV), which are used in the prognosis and prediction of diseases in new studies in the literature, are useful for predicting early-onset preeclampsia.
METHODS: The first group consisted of healthy pregnant women who had a single foetus without any additional disease between 24 and 34 gestational weeks, and the second group consisted of pregnant women who were diagnosed with early-onset preeclampsia and did not have any additional disease or foetal anomalies during the same gestational week. Neutrophil, lymphocyte, monocyte, thrombocyte, ALB, pan immune inflammation value (PIV) and prognostic nutritional index (PNI) scores were recorded.
RESULTS: In our case control study, 70 patients with early-onset preeclampsia and 140 pregnant women composed the normotensive (control) group. There was a significant difference between the groups according to PIV (p = 0.04). The prognostic nutritional index (PNI) was significantly lower in the early-onset preeclampsia group than in the normotensive group (p < 0,001). A PNI lower than 36, 30 could only predict early-onset preeclampsia with a low sensitivity of 31.1% and specificity of 45%; the area under the curve was 0,24 (95% confidence interval 0.18-0.31), p < 0,001.
CONCLUSION: Patients with PNI scores lower than 36,30 may have early-onset preeclampsia.
The invention relates to a novel composition of indiplon with low dissolvability in a water-based solvent, a method for preparing the novel composition, and an oral preparation comprising the novel composition. More particularly, the invention relates to an oral composition of the indiplon, which has the function of improving the dissolution. The novel composition is characterized by comprising micronized indiplon, wherein micronization technologies comprise fluid energy milling, ball grinding, recrystallizing, solid-state dispersing and the like. A solid composition also comprises at least one solubilizer selected from Tween-80 or lauryl sodium sulfate. The invention also relates to a preparation method of the novel composition and the oral preparation prepared by adopting the preparation method. According to the invention, the composition of indiplon for improving oral absorption through improving dissolution can be obtained. The oral solid composition of indiplon can express that the dissolubility is improved under the in vitro dissolution condition.
This is the next part of the project under a National Institute of Drug Abuse-funded R01 treatment development study with the purpose of developing a computer-based augmentation of standard drug counseling for cocaine dependence. This project has received additional funding from NIDA. Specifically, the aims of the next part of the proposal are to develop and manualize a cue-exposure based cocaine treatment using virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions. We will enroll a total of 270 cocaine dependent subjects in order to meet the target goal of 180 subjects in treatment. This randomized clinical trial will be conducted in order to determine the acceptability and feasibility of this treatment to subjects and therapists, and to obtain treatment outcome effect size estimates. Specifically, during the next stage of the study, 180 cocaine dependent individuals will be randomly assigned to receive a NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment or I/GDC plus VR/CER. Matching between treatment groups will be based on age, sex, severity of crack use (using the Addiction Severity Index), and presence or absence of antisocial personality disorder. Treatment assignment will be conducted using a computerized urn matching program by the off-site study statistician. Current psychiatric diagnoses will be assessed, as will changes in crack use. Comprehensive assessments will be conducted during treatment at baseline, and at a six-month and twelve-month follow-up. To measure outcomes, substance use will be assessed via self-report and urinary analysis three times weekly during 24 weeks of active treatment and weekly during six month and twelve month of follow-up assessment.

This new larger part of project follows work we have conducted in a NIDA-funded pilot project over the past four years, developing the complementary intervention. In our preliminary studies (Phase I a/b), we conducted focus groups, an open trial, and a small randomized controlled trial (n = 53) to demonstrate the promise of the novel intervention. The pilot phase I a/b portion enrolled 171 subjects (signed consent) at Duke. 19 of 53 completed the treatment portion. During Phase 1a, the VR and CER technology was developed and refined using two small open clinical trials. At the conclusion of Phase 1a, a treatment manual detailing the rationale and parameters of VR and CER technology was completed. Next, as mentioned, a Phase Ib pilot randomized clinical trial was conducted in order to determine the acceptability and feasibility of this treatment to patients and therapists, and to obtain treatment outcome effect size estimates.
Dentin hypersensitivity (DH) is a very common complaint that occurs in the general population. The intensity of the pain can be minor to very serious, which may prevent one from eating or performing ordinary oral hygiene practices. The most accepted mechanism by which DH occurs is hydrodynamic theory, which suggests that pain-producing stimuli cause rapid movement of fluid within the dentin tubules, as a result the free nerve endings, at the inner ends of the tubules or the periphery of the pulp, are excited and DH occurs. According to this theory, one approach to treat DH is reducing dentin tubule fluid movement through occluding open tubules. Strontium chloride was the first tubule-blocking ingredient used in dentifrice about fifty years ago and since that time a paucity of clinical studies have been carried out to test its effectiveness on DH. The other approach is to reduce the pulp nerve excitability by depolarizing the nerve endings, in which the most widely used material is potassium salts. Although there is limited clinical evidence that dentifrices containing strontium chloride or potassium nitrate alone, as the major desensitizing agent, has an effect on reducing DH, no clinical studies have shown the effectiveness of a dentifrice containing both strontium chloride and potassium nitrate in a silica base on alleviating DH.
The present disclosure relates to a pharmaceutical formulation and a process for its preparation. The pharmaceutical formulation comprises cinnamic acid and at least one excipient. The pharmaceutical formulation of the present disclosure has improved patient compliance, and reduced adverse effects. The pharmaceutical formulation of the present disclosure can be used in the treatment of cyclophosphamide induced neutropenia. The present disclosure further relates to a process of preparing the cinnamic acid. The process is simple and economical.
FIELD: medicine. ^ SUBSTANCE: treatment of chronic gonorrheal and gonorrheal-bacterial urethritis is ensured by antibiotic therapy and local treatment of clarithromycin in a liposomal form in the concentration 0.015 mg/ml, temperature 24-28C. A length of procedure is 10-15 minutes. The therapeutic course is 5-7 days. ^ EFFECT: prevented recurrent disease, reduced side effects and complications due to localisation of antibacterial, antiinflammatory and phagocytosis stimulating action of clarithromycin by its delivery into a cell phagocyting Ngonorrhoeae and Saureus with higher antibiotic resistance. ^ 2 ex, 3 tbl
The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and/or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.
The investigators will recruit 66 couples in which one person has type 2 diabetes. Power is based on effect sizes from previous couple intervention studies and meta-analyses on primary outcomes. Couples will be randomly assigned to either a communal coping intervention or an attention (diabetes education) control group. All couples will come to the laboratory or meet via zoom, complete a baseline questionnaire assessment (primary and secondary outcomes, mediators) and have a videotaped conversation about how they cope with diabetes. The intervention group will receive the communal coping intervention. Couples in the intervention group will identify 5 collaborative implementation intentions, whereas controls will identify 5 individual implementation intentions. After the in-person session, couples will individually complete a daily diary at the end of the day for 14 consecutive days which focuses on daily communication, mood, and patient self-care. During the first 7 days, the intervention group will receive two text messages per day (morning focus on shared appraisal, evening focus on one of collaborative implementation intentions identified during in-person session). An in-person follow-up interview will take place 6 weeks after the initial session, during which primary outcomes, secondary outcomes, and mediators will be assessed and the videotaped conversation repeated.
Patients receive one of 4 doses of alpha-TEA PO on days 1-14 of each cycle. Patients also receive trastuzumab on day 1 of cycle 1 and then every 3 weeks per standard of care. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is:

Pregabalin is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35.

LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 75mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide.